Journal of Clinical Medicine (Aug 2023)

Duchenne Muscular Dystrophy from Brain to Muscle: The Role of Brain Dystrophin Isoforms in Motor Functions

  • Nalaka Wijekoon,
  • Lakmal Gonawala,
  • Pyara Ratnayake,
  • Dhammika Amaratunga,
  • Yetrib Hathout,
  • Chandra Mohan,
  • Harry W. M. Steinbusch,
  • Ashwin Dalal,
  • Eric P. Hoffman,
  • K. Ranil D. de Silva

DOI
https://doi.org/10.3390/jcm12175637
Journal volume & issue
Vol. 12, no. 17
p. 5637

Abstract

Read online

Brain function and its effect on motor performance in Duchenne muscular dystrophy (DMD) is an emerging concept. The present study explored how cumulative dystrophin isoform loss, age, and a corticosteroid treatment affect DMD motor outcomes. A total of 133 genetically confirmed DMD patients from Sri Lanka were divided into two groups based on whether their shorter dystrophin isoforms (Dp140, Dp116, and Dp71) were affected: Group 1, containing patients with Dp140, Dp116, and Dp71 affected (n = 98), and Group 2, containing unaffected patients (n = 35). A subset of 52 patients (Group 1, n = 38; Group 2, n = 14) was followed for up to three follow-ups performed in an average of 28-month intervals. The effect of the cumulative loss of shorter dystrophin isoforms on the natural history of DMD was analyzed. A total of 74/133 (56%) patients encountered developmental delays, with 66/74 (89%) being in Group 1 and 8/74 (11%) being in Group 2 (p p p = 0.004). DMD motor dysfunction is linked to DMD mutations that affect shorter dystrophin isoforms. When stratifying individuals for clinical trials, considering the DMD mutation site and its impact on a shorter dystrophin isoform is crucial.

Keywords